» Authors » Janakiraman Subramanian

Janakiraman Subramanian

Explore the profile of Janakiraman Subramanian including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 78
Citations 2188
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ponvilawan B, Bansal D, Karim N, Ramakrishnan R, Subramanian J
JAMA Netw Open . 2025 Feb; 8(2):e2457357. PMID: 39937485
No abstract available.
2.
Subramanian J, Gregg J, Berktas M, Li J, Leighl N
Lung Cancer . 2025 Feb; 201:108412. PMID: 39933217
Objectives: Guidelines recommend epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small cell lung cancer (NSCLC) and initiation of first-line EGFR tyrosine kinase inhibitors (EGFR-TKIs) for EGFR...
3.
Karim N, Rabea A, Mack P, Subramanian J, Khalil E, Sherif M, et al.
JTO Clin Res Rep . 2025 Jan; 6(1):100776. PMID: 39790369
Lung cancer remains a leading cause of cancer-related mortality globally and presents significant challenges in Egypt. In 2023, the first annual meeting of the Thoracic Oncology Multidisciplinary Faculty, organized by...
4.
Karim N, Zaza M, Subramanian J
Transl Lung Cancer Res . 2024 Sep; 13(8):2098-2102. PMID: 39263035
No abstract available.
5.
Ponvilawan B, Subramanian J, Bansal D
J Thorac Oncol . 2024 Aug; 19(8):e24-e26. PMID: 39112009
No abstract available.
6.
Gandara D, Subramanian J, Santos E, Brody Y, Sela I, Elon Y, et al.
Clin Lung Cancer . 2024 Jul; 25(6):e252-e261.e4. PMID: 39034168
Purpose: Immune Checkpoint Inhibitor (ICI) regimens are approved for first-line treatment of metastatic nononcogene-driven NSCLC. Guidelines do not differentiate which patients with PD-L1 ≥ 50% should receive ICI monotherapy. The...
7.
Princic N, Marrett E, Kwong W, McMorrow D, Schwartz H, Subramanian J
Future Oncol . 2024 Jul; 20(24):1753-1764. PMID: 39011928
Compare healthcare costs for patients with epidermal growth factor receptor mutated (EGFRm) metastatic non-small-cell lung cancer (mNSCLC) with and without progression and estimate costs of progression. Retrospective claims analysis (2015-2020)...
8.
Sharma P, Mahadevia H, Donepudi S, Kujtan L, Gustafson B, Ponvilawan B, et al.
Clin Lung Cancer . 2024 May; 25(5):479-482. PMID: 38777674
No abstract available.
9.
Mahadevia H, Ponvilawan B, Al-Obaidi A, Buckley J, Subramanian J, Bansal D
Ther Adv Med Oncol . 2024 Apr; 16:17588359241242406. PMID: 38559611
Immune checkpoint inhibitors (ICIs) and poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in various tumors. A significant therapeutic challenge with either ICIs or PARP inhibitors as monotherapy is treatment...
10.
Ponvilawan B, Khan A, Subramanian J, Bansal D
Cancers (Basel) . 2024 Mar; 16(6). PMID: 38539558
Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of...